Abstract
Alopecia areata (AA) is a nonscarring and recurrent disease characterized by hair loss that may significantly affect patient health-related quality of life (HRQoL). Given the lack of reliable and accurate reporting of HRQoL status in patients with AA, we analyzed data from 532 AA patients from the National Alopecia Areata Registry whose registry record included HRQoL assessments using three validated instruments: Skindex-16, brief version of the Fear of Negative Evaluation Scale, and Dermatology Life Quality Index. The mean HRQoL scores were compared with previously reported HRQoL levels from healthy controls and patients with other skin diseases. Two-step cluster analysis of Skindex-16 scales divided patients into two groups: 481 (57%) with good HRQoL and 361 (43%) with poor HRQoL. Multivariate logistic regression modeling revealed a set of risk factors for poor HRQoL: age <50 years (odds ratio (OR) 3.99, 95% confidence interval (CI) 1.66–9.58), female gender (OR 2.74, 95% CI 1.73–4.34), hair loss 25–99% (OR 2.47, 95% CI 1.12–5.45), family stress (OR 1.8, 95% CI 1.13–2.86), and job change (OR 2.01, 95% CI 1.02–3.94). The current analysis provides an overview of the HRQoL status of AA patients and may guide patient care in the future.
| Original language | English (US) |
|---|---|
| Pages (from-to) | S49-S50 |
| Journal | Journal of Investigative Dermatology Symposium Proceedings |
| Volume | 16 |
| Issue number | 1 |
| DOIs | |
| State | Published - Dec 2013 |
Bibliographical note
Funding Information:We thank the many patients and their family members who participated in the National Alopecia Areata Registry, to the National Alopecia Areata Foundation (NAAF) for funding and to V. Kalabokes and her staff at NAAF for their efforts. Funding for the Summit and publication of this article was provided by the National Alopecia Areata Foundation. MH has received consulting fees from Procter and Gamble, Pantene Institute, and Allergan. MH has also received grant support from Medicis, Allergan, and Novartis Corporation. The other authors state no conflict of interest.
Funding Information:
MH has received consulting fees from Procter and Gamble, Pantene Institute, and Allergan. MH has also received grant support from Medicis, Allergan, and Novartis Corporation. The other authors state no conflict of interest.
Funding Information:
We thank the many patients and their family members who participated in the National Alopecia Areata Registry, to the National Alopecia Areata Foundation (NAAF) for funding and to V. Kalabokes and her staff at NAAF for their efforts. Funding for the Summit and publication of this article was provided by the National Alopecia Areata Foundation.
Publisher Copyright:
© 2013 The Society for Investigative Dermatology, Inc